Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Biomarkers
Female
Gene Expression Regulation, Neoplastic
Hematopoietic Stem Cell Transplantation
Humans
Immune Reconstitution
Kaplan-Meier Estimate
Lymphocyte Count
Male
Multiple Myeloma
/ etiology
Neoplasm Grading
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Receptors, Immunologic
/ genetics
T-Lymphocyte Subsets
/ immunology
Transplantation, Autologous
Treatment Outcome
Ki-67
PD-1
T cell receptor
autologous stem cell transplant
immune phenotype
multiple myeloma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
10
2020
accepted:
21
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The benefit of autologous stem cell transplantation (ASCT) in newly diagnosed myeloma patients, apart from supporting high dose chemotherapy, may include effects on T cell function in the bone marrow (BM). We report our exploratory findings on marrow infiltrating T cells early post-ASCT (day+100), examining phenotype and T cell receptor (TCR) repertoire, seeking correlations with timing of relapse. Compared to healthy donors (HD), we observed an increase in regulatory T cells (CD4+FoxP3+, Tregs) with reduction in CD4 T cells, leading to lower CD4:8 ratios. Compared to paired pre-treatment marrow, both CD4 and CD8 compartments showed a reduction in naïve, and increase in effector memory subsets, suggestive of a more differentiated phenotype. This was supported by increased levels of several immune-regulatory and activation proteins (ICOS, PD-1, LAG-3, CTLA-4 and GzmB) when compared with HD. Unsupervised analysis identified a patient subgroup with shorter PFS (p=0.031) whose BM contained increased Tregs, and higher immune-regulatory markers (ICOS, PD-1, LAG-3) on effector T cells. Using single feature analysis, higher frequencies of marrow PD-1+ on CD4+FoxP3- cells and Ki67+ on CD8 cells were independently associated with early relapse. Finally, studying paired pre-treatment and post-ASCT BM (n=5), we note reduced abundance of TCR sequences at day+100, with a greater proportion of expanded sequences indicating a more focused persistent TCR repertoire. Our findings indicate that, following induction chemotherapy and ASCT, marrow T cells demonstrate increased activation and differentiation, with TCR repertoire focusing. Pending confirmation in larger series, higher levels of immune-regulatory proteins on T cell effectors at day+100 may indicate early relapse.
Identifiants
pubmed: 33717112
doi: 10.3389/fimmu.2021.618610
pmc: PMC7946836
doi:
Substances chimiques
Biomarkers
0
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
618610Subventions
Organisme : Medical Research Council
ID : MR/S001883/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C416/A25145
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Lee, Alrasheed, Khandelwal, Fitzsimons, Richards, Wilson, Chavda, Henry, Conde, De Massy, Chin, Galas-Filipowicz, Herrero, Chain, Quezada and Yong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2015;56(9):2668-73
pubmed: 25573201
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Front Immunol. 2017 Apr 13;8:430
pubmed: 28450864
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Nat Med. 2019 Oct;25(10):1549-1559
pubmed: 31591606
Leuk Lymphoma. 2009 Nov;50(11):1860-4
pubmed: 19883313
Blood. 2012 Jan 19;119(3):687-91
pubmed: 22128143
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
J Clin Invest. 2019 Jan 2;129(1):106-121
pubmed: 30300141
J Exp Med. 2016 Aug 22;213(9):1799-818
pubmed: 27481131
J Immunol. 2013 May 1;190(9):4899-909
pubmed: 23536636
Cancer Cell. 2018 Apr 9;33(4):634-648.e5
pubmed: 29551594
Cell Oncol (Dordr). 2018 Feb;41(1):1-11
pubmed: 28994018
Bioinformatics. 2013 Mar 1;29(5):542-50
pubmed: 23303508
J Clin Invest. 2014 Mar;124(3):1168-72
pubmed: 24531550
Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44
pubmed: 16864054
Blood. 2018 Oct 18;132(16):1675-1688
pubmed: 30154111
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Int Immunol. 2018 Feb 3;30(1):13-22
pubmed: 29294043
Cancer Immunol Res. 2016 Jan;4(1):61-71
pubmed: 26464015
J Clin Invest. 2018 Jun 1;128(6):2487-2499
pubmed: 29558366
Lancet Haematol. 2016 Jul;3(7):e306-7
pubmed: 27374462
Bone Marrow Transplant. 2001 Oct;28(7):673-80
pubmed: 11704790
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Semin Immunol. 2007 Oct;19(5):318-30
pubmed: 18023361
Int J Clin Exp Med. 2015 Feb 15;8(2):1803-13
pubmed: 25932108
Semin Immunol. 2016 Feb;28(1):28-34
pubmed: 26976826
Clin Cancer Res. 2020 Jul 1;26(13):3443-3454
pubmed: 32220887